Who We Are

Editorial Staff

Associate Editorial Director: Janelle Bradley
jbradley@hmpglobal.com

Managing Editor: Stephanie Holland
sholland@hmpglobal.com

Managing Editor: Kirra Fedyszyn
kfedyszyn@hmpglobal.com

Associate Editor: Emily Estrada
eestrada@hmpglobal.com

Business Staff

Director, Oncology Omnimedia Sales: Erin Statmore
estatmore@hmpglobal.com

Senior Manager, National Accounts: Stephanie Makowski
smakowski@hmpgobal.com

Digital Operations Staff

Director, Digital Revenue Operations: Katelynn McFadden

Assistant Director, Digital Operations: Nina Fischang

Senior Manager, Digital Operations: Addison Fish

Associate Manager, Digital Operations: Cady Cohen

Corporate Staff

Chief Executive Officer: Jeff Hennessy

Chief Financial Officer: Greg Salter

President & Chief Operating Officer: Jeff Hennessy, Jr.

Chief Strategy & Corporate Development Officer: Mark Miller

Chief HR Officer/Executive Vice President, Operations: Anthony Mancini

Senior Vice President, Content Development & Operations: David DePinho

Executive Vice President, Business Development & Product Strategy: Kara Rosania

Vice President, Information Technology: Tim Shaw

Recent News

FDA Approval

FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome

07/13/2026

Stephanie Holland

The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...

The FDA approved ENNUMO, a...

07/13/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma

07/13/2026

Stephanie Holland

The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...

The FDA accepted the new drug...

07/13/2026

Oncology

News

Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

07/10/2026

Stephanie Holland

Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...

Interim results from the phase...

07/10/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma

07/10/2026

Emily Estrada

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

The FDA has approved...

07/10/2026

Oncology

News

Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...

A multicenter real-world study...

07/09/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

News

Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...

Results from a multicenter...

07/09/2026

Oncology

News

Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma

07/09/2026

Stephanie Holland

Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...

Results from a phase 1 trial...

07/09/2026

Oncology

News

First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia

07/09/2026

Stephanie Holland

Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...

Results from the ongoing, phase...

07/09/2026

Oncology